SC
DYN icon

SummitTX Capital’s Dyne Therapeutics DYN Stock Holding History

SummitTX Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.56M Sell
196,188
-47,088
-19% -$812K 0.11% 213
2025
Q4 		$4.76M Buy
243,276
+110,376
+83% +$2.09M 0.14% 165
2025
Q3 		$1.68M Buy
132,900
+13,939
+12% +$159K 0.07% 290
2025
Q2 		$1.13M Sell
118,961
-10,897
-8% -$120K 0.05% 347
2025
Q1 		$1.36M Buy
+129,858
New +$1.86M 0.06% 328

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

SummitTX Capital's DYN Position: Q1 2026 in Review

SummitTX Capital reduced its Dyne Therapeutics (DYN) stake by 19% in Q1 2026, selling an estimated $812K and leaving 196,188 shares worth $3.56M. The position accounts for 0.11% of the portfolio, ranked #213.

SummitTX Capital first reported a position in DYN in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.76M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • SummitTX Capital held 196,188 shares of Dyne Therapeutics worth $3.56M as of Q1 2026.
  • SummitTX Capital sold 47,088 Dyne Therapeutics shares in Q1 2026, an estimated $812K.
  • Dyne Therapeutics made up 0.11% of SummitTX Capital's portfolio in Q1 2026, its #213 holding.
  • SummitTX Capital first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Dyne Therapeutics position peaked at $4.76M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.